K-Run Co., Ltd. (CEO Han Cheong-su) announced that on the 20th it signed a three-party agreement with the Osong Medical Innovation Foundation (Chairman Lee Myung-soo, hereinafter Osong Foundation) and Young Science Co., Ltd. (CEO Jung Tae-hoon) to implement a project for establishing process technology services for nucleic acid therapeutics formulation.

Under this agreement, K-Run plans to support the project to build process technology services for nucleic acid therapeutics formulation and production by providing, together with Young Science, essential equipment for nucleic acid therapeutics formulation processes, including the NanoKRAShoT CLINICA system developed and manufactured in-house.

Nucleic acid therapeutics are innovative pharmaceuticals that use nucleic acid molecules such as DNA or RNA to correct or treat the causes of diseases at the genetic level. They include gene therapies, mRNA vaccines, and RNA interference (RNAi) therapeutics, and have recently seen active development. These therapeutics can be applied to treat a wide range of diseases, including genetic disorders, cancers, and viral infections, which have been difficult to address with conventional drugs.

The supported equipment will be applied to core processes for LNP (Lipid Nanoparticles) formulation of nucleic acid therapeutics. The Osong Foundation will introduce related core process equipment and work to establish a service system within the first half of 2026. The foundation plans to enhance process completeness through stepwise qualification (DQ·IQ·OQ) in accordance with GMP standards and to strengthen process reliability based on demonstration by conducting Performance Qualification (PQ) in cooperation with client companies.

K-Run is a domestic venture company that has developed a lipid nanoparticle (LNP) manufacturing system using purely domestic technology based on semiconductor process technology, and has been supplying its systems to bio-venture companies and research institutes in the domestic nucleic acid therapeutics and drug delivery system sectors. Its technological capabilities have been recognized through its selection under the Ministry of Science and ICT’s innovative product designation system in 2024 and its selection for the Innovation Premier 1000 in 2025. Based on this agreement, the company plans to support the Osong Foundation’s technology verification and process scale-up.

K-Run CEO Han Cheong-su stated, “This agreement will serve as an opportunity to pursue verification and secure reliability of domestic technologies through cooperation with the Osong Foundation in a domestic bio materials, parts, and equipment market dominated by global companies,” adding, “We will support domestic nucleic acid therapeutics companies, which have a high dependence on overseas technologies, in securing validation capabilities for clinical readiness through this process support, and help this lead to the creation of domestic pipelines for advanced new drugs.”

Popular News